The dynamics and direction of changes at various stages of the cardiovascular disease continuum in the serum fibrosis markers, MMP-9 and TIMP-1 systems, may reflect an increase in fibrotic and decrease in antifibrotic processes already at the preclinical stage of HF. Here, MMP9 is linked to cardiovascular disorder.